Carriers of the rs10508884C allele in CXCL12 responded more poorly to anti-TNFs in the Kaplan–Meier univariate analysis (p = 0.049), although statistical significance was lost in a Cox regression analysis adjusted for sex, type of IBD, and type of anti-TNF drug (adjusted hazard ratio 0.309; 95% CI 0.076–1.268, p = 0.103). Here, CXCL12 is linked to inflammatory bowel disease.